Dr. Rule on Potential for CAR T-Cell Therapy in MCL

Video

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma (MCL).

Data on using CAR T-cell therapy to treat patients with MCL will be presented at the 2019 ASH Annual Meeting. Rule is hoping CAR T-cell therapy will be a contributing treatment and believes it will work best post-BTK inhibitor.

CAR T-cell therapy may even have the potential to replace allogeneic stem cell transplant, according to Rule. This would be a positive advance because many physicians do not like the toxicity associated with allogeneic stem cell transplant, particularly graft-versus-host disease. However, long-term data are necessary before CAR T-cell therapy is used in place of allogeneic stem cell transplant, concludes Rule.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.